求助书籍

wenwen629

Dübel, Stefan (ed.)+ K; W5 P; ?' p# W- D6 m: l3 h- d0 k
Handbook of Therapeutic Antibodies
' R0 j4 q/ R1 J: o3 y/ wTechnologies, Emerging Developments and Approved Therapeutics
% R! L4 i/ k  A, P# b: a
6 ?( [4 u# h' p' J1. Edition - July 2010/ M/ e; ?- p/ V) N
199.- Euro
( c& a* P+ g! n3 f  Y2010. XLVI, 1204 Pages, Softcover% `! X0 ~/ i6 L# ~  S  W
200 Fig. (100 Colored Fig.)
4 @* R# k+ }% a) Q9 R- Handbook/Reference Book -
% N/ |) a0 r% r  yISBN-10: 3-527-32902-13 S8 D7 s* F' m/ W) a' h  S" e
有目录也可，求书！

wenwen629

回复 hdc2001 的帖子$ q  u, Y# U7 Y- o( z' Q
, ]. G6 T/ r( B5 E* r: D" `, m. p
谢谢。

hdc2001

Section I: Technologies
4 s; d- v) x( V8 K/ w+ U2 UForeword
+ k2 ^( l. u2 ~, {A Greeting from the Editor# o/ ]4 V" t2 K: o1 a
PART 0: INTRODUCTION
5 Y# V9 R9 p" c& E- C. Q; M4 GTherapeutic Antibodies - From Past to Future
/ m8 G1 G( \2 X2 N# m9 @PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE- s- o2 f3 Q1 }3 Q( K7 D3 m
Selection strategies I: Monoclonal Antibodies
" s3 ?6 |# ?( v( ?9 G# i! D' ?1 [% fSelection strategies II: Antibody Phage Display/ B/ k: H# M: C( _/ R$ l- j2 d+ H
Selection strategies III: Transgenic Mice
+ q4 A$ \, i( E1 c; F3 p+ cBioinformatic Tools for Antibody Engineering2 K1 M8 @1 h0 u- |
Molecular Engineering I: Humanization
. q4 k8 S; h7 F6 C6 K( dMolecular Engineering II: Affinity Maturation " [* a6 f) \2 z% U7 D9 V% r1 }
Molecular Engineering III: Fc Engineering
& B5 Z; Y' Q4 k% z( QPART II: THE WAY INTO THE CLINIC5 D+ p1 ]# c4 a" x
Production and Downstream Processing
' B( Q  o9 _3 n9 s0 _( n+ n& dPharmaceutical Formulation and Clinical Application
5 t. F: B. @0 s! {5 W, aImmunogenicity of Antibody Therapeutics
' x7 W- e7 j1 h! S- nRegulatory Considerations
1 t  p0 ]% u6 l# JIntellectual Property Issues , i6 Y6 o" K+ t0 C

# F( ~2 ]8 W+ b/ x; z& l  TSection II: Emerging Developments" }* _, h+ D. ~, ]3 W* D
PART III: BEYOND IGG: MODIFIED ANTIBODIES$ o& n' Q( ]$ k6 @1 |+ l% C
Immunoscintigraphy and Radioimmunotherapy % H4 c! b  S9 R- b2 T
Bispecific Antibodies
& {( N. ~0 H. }Immunotoxins /
7 V! Q  ?  j& q( D: ?2 n/ yTargeted RNases 8 j$ i6 q" J+ M! x) k, V4 a
PART IV: EMERGING CONCEPTS/ I6 r/ w1 k% d0 c' _
Automation of Selection and Engineering ' j0 m" V$ O; P6 a3 {; U$ z
Emerging Technologies for Antibody Selection
" Q# A2 w' \7 N: I, k/ K  Y& IEmerging Alternative Production Systems 5 e8 S7 b4 x3 n* n
Non-Antibody Scaffolds
7 F; J; h9 l) d! E0 BEmerging Therapeutic Concepts I: ADEPT
1 T  F& n) j  b5 ?5 S( z# AEmerging Therapeutic Concepts II: Nanotechnology
* C% d2 f# Z9 e, W$ jEmerging Therapeutic Concepts III:Cell-bound antibodies
5 q( u- K' J  R5 v$ s: ]Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies- T; ^9 |! z  P7 ]0 M1 R% h) f% \
PART V: ONGOING CLINICAL STUDIES:
9 u% j+ j4 Q7 a1 B# x* l. sAntibodies in Phase I/II/III: Cancer Therapy 2 V8 A4 C2 e) i' ~6 ~: O+ o
Antibodies in Phase I/II/III: Targeting TNF
) O5 H3 ^' w$ J( t& z- V; i7 u2 k) J" ?
Section III: APPROVED THERAPEUTICS
& R& t1 a) e+ e* `( p# M& J$ j6 hAdalimumab (Humira)% P" R% {- X# E3 E
Alemtuzumab (Mabcampath)
2 f9 X8 S# |/ oBevacizumab (Avastin)7 T$ G% z+ Z. \. C; L1 [- v
Cetuximab (Erbitux)
1 M% t- v7 s) i# F  ^9 @Efalizumab (Raptiva)7 m& c, ?  }# n2 |, K3 e3 b* @
Fanolesomab/Technetium99m (Neutrospec)
& g" e/ O; v. h- \Gemtuzumab Ozogamicin (Mylotarg)
/ J4 u) c& J, O6 O# p, fInfliximab (Remicade)( n- k0 ~* ~1 g9 b5 C4 D( o# v
Muromonab (Orthoclone)$ p; ]4 r; l9 j; i& t: a3 }+ S  n
Natalizumab (Tysabri)! F+ ~, I; E2 S
Omalizumab (Xolair)" L7 A. C9 m' x2 C" H1 D) I+ b5 ?. X
Palivizumab (Synagis)
* |  M3 h# J- _- x. MRituximab (Rituxan)  x8 j9 V# Z4 E0 r8 \( V6 v- j
Trastuzumab (Herceptin)1 I5 ?. m4 S' j
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab0 o8 }* `3 `1 D
Yttrium-90 Ibritumomab Tiuxetan (Zevalin)9 m6 t1 Q8 ]; A' p% l0 w; g: u

hdc2001

我也想要。